{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:10:46Z","timestamp":1768785046960,"version":"3.49.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.6995","type":"journal-article","created":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T22:14:09Z","timestamp":1483222449000},"page":"73-78","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of Combined Therapy with Pirfenidone and Erythromycin for Unclassifiable Interstitial Pneumonia Induced by HTLV-1-associated Bronchioloalveolar Disorder (HABA)"],"prefix":"10.2169","volume":"56","author":[{"given":"Naoko","family":"Yokohori","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizue","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Katsura","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Tokyo Women's Medical University Yachiyo Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[{"name":"Division of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Takemura","sequence":"additional","affiliation":[{"name":"Division of Pathology, Japanese Red Cross Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kimura I. HTLV-1 associated bronchiolo-alveolar disorder (HABA). Nihon Kyobu Rinshou 47: 283-293, 1988 (in Japanese)."},{"key":"2","unstructured":"2. Kimura I. HABA (HTLV-1 associated bronchiolo-alveolar disorder). Nihon Kyobu Shikkan Gakkai Zasshi 30: 787-795, 1992 (in Japanese, Abstract in English)."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Yamazato Y, Miyazato A, Kawakami K, Yara S, Kaneshima H, Saito A. High expression of p40<sup>tax<\/sup> and pro-inflammatory cytokines and chemokines in the lungs of human T-lymphotropic virus type 1-related bronchopulmonary disorders. Chest 124: 2283-2292, 2003.","DOI":"10.1378\/chest.124.6.2283"},{"key":"4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2249.1994.tb06541.x","volume":"96","author":"Y Higashiyama","year":"1994","unstructured":"4. Higashiyama Y, Katamine S, Kohno S, et al. Expression of human T lymphotropic virus type I (HTLV-1) <i>tax\/rex<\/i> gene in fresh bronchoalveolar lavage cells of HTVL-1 infected individuals. Clin Exp Immunol 96: 193-201, 1994.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2249.2000.01237.x","volume":"120","author":"M Seki","year":"2000","unstructured":"5. Seki M, Higashiyama A, Mizokami J, et al. Up-regulation of human T lymphotropic virus type 1 (HTLV-1) <i>tax\/rex<\/i> mRNA in infected lung tissues. Clin Exp Immunol 120: 488-498, 2000.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Teruya H, Tomita M, Senba M, et al. Human T-cell leukemia virus type I infects human lung epithelial cells and induces gene expression of cytokines, chemokines and cell adhesion molecules. Retrovirology 5: 86, 2008.","DOI":"10.1186\/1742-4690-5-86"},{"key":"7","unstructured":"7. Araki J, Kaku M, Mashimoto H, Fukuda Y, Asai S. A case of HTLV-1 associated myelopathy with pulmonary involvement. Nihon Kyobu Shikkan Gakkai Zasshi 27: 1375-1379, 1989 (in Japanese, Abstract in English)."},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Kadota J, Mukae H, Fujii T, Seki M, Tomono K, Kohno S. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 125: 1239-1247, 2004.","DOI":"10.1378\/chest.125.4.1239"},{"key":"9","unstructured":"9. Kimura I, Tsubota T, Tada S, Sogawa J. Presence of antibodies against adult T cell leukemia antigen in the patients with chronic respiratory disease. Acta Med Okayama 40: 281-284, 1986."},{"key":"10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1378\/chest.95.3.708a","volume":"95","author":"M Sugimoto","year":"1989","unstructured":"10. Sugimoto M, Nakashima H, Kawano O, Ando M, Araki S. Bronchoalveolar T-lymphocytosis in HTLV-1-associated myelopathy. Chest 95: 708, 1989.","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"11","unstructured":"11. Sugimoto M, Mita S, Tokunaga M, et al. Pulmonary involvement in human T lymphotropic virus type-1 uveitis: T-lymphocytosis and high proviral DNA load in bronchoalveolar lavage fluid. Eur Respir J 6: 938-946, 1993."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sugimoto M, Kitaichi M, Ikeda A, Nagai S, Izumi T. Chronic bronchioloalveolitis associated with human T-cell lymphotrophic virus type I infection. Curr Opin Pulm Med 4: 98-102, 1998.","DOI":"10.1097\/00063198-199803000-00007"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yu H, Fujita J, Higa F, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement in human T-cell lymphotropic virus type I carriers. J Infect Chemother 5: 284-287, 2009.","DOI":"10.1007\/s10156-009-0707-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakayama Y, Yamazato Y, Tamayose M, et al. Increased expression of <i>HBZ<\/i> and <i>Foxp3<\/i> mRNA in bronchoalveolar lavage cells taken from human T-lymphotropic virus type 1-associated lung disorder patients. Intern Med 52: 2599-2609, 2013.","DOI":"10.2169\/internalmedicine.52.0845"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Raghu G, Collard HR, Egan JJ, et al; ATS\/ERS\/JRS\/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.","DOI":"10.1164\/rccm.2009-040GL"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 177: 1338-1347, 2008.","DOI":"10.1164\/rccm.200611-1685OC"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-\u03b2 gene expression at the transcription level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367-373, 1999.","DOI":"10.1016\/S0022-3565(24)35110-9"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Tanaka K, Azuma A, Miyazaki Y, Sato K, Mizushima T. Effects of lecithinized superoxide dismutase and\/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest 142: 1011-1019, 2012.","DOI":"10.1378\/chest.11-2879"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 20: 400-408, 2008.","DOI":"10.1016\/j.ejphar.2008.06.046"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Taniguchi M, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829, 2010.","DOI":"10.1183\/09031936.00005209"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lederer DJ, Bradford WZ, Fagan EA, et al. Sensitivity analyses of the change in forced vital capacity in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis. Chest 10: 2814-2817, 2015.","DOI":"10.1378\/chest.14-2817"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kohyama T, Yamauchi Y, Takizawa H, et al. Clarisromycin inhibits fibroblast migration. Respir Med 102: 1769-1776, 2008.","DOI":"10.1016\/j.rmed.2008.06.020"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pathak V, Kuhn JM, Durham C, Funkhouser WK, Henke DC. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. Ann Am Thorac Soc 11: 87-91, 2014.","DOI":"10.1513\/AnnalsATS.201308-261CR"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/1\/56_56.6995\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:42:16Z","timestamp":1749858136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/1\/56_56.6995\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.6995","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}